Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SCD | O00767 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | VNN1 | O95497 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.43 |
| ▸ | TCF7L2 | Q9NQB0 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | CFTR | P13569 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL939862 | 0.90 | ADORA2A (0.47) | ADORA2AADORA1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL5254988 | 0.89 | ADORA3 (0.53) | ADORA2AADORA1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL29371671 | 0.89 | ADORA3 (0.53) | ADORA2AADORA1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL939909 | 0.89 | CTNNB1 (0.49) | ADORA2AADORA1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL940842 | 0.88 | FLT3 (0.47) | ADORA2AADORA1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL2011630 | 0.88 | ADORA2A (0.42) | ADORA2AADORA1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL5784594 | 0.87 | EGFR (0.49) | ADORA2AADORA1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL940231 | 0.87 | ADORA2A (0.45) | ADORA2AADORA1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL940905 | 0.86 | ADORA2A (0.44) | ADORA2AADORA1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL943367 | 0.86 | ADORA2A (0.44) | ADORA2AADORA1LMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964731-B2 | Isotopically marked quinoline derivatives as adenosin A3 receptor ligands | SANOFI-AVENTIS (FR) | 2011-06-21 | — | — | US | disclosed |
| EP-1814857-B1 | ISOTOPICALLY MARKED QUINOLINE DERIVATIVES AS ADENOSIN A3 RECEPTOR LIGANDS | SANOFI AVENTIS (FR) | 2010-09-01 | — | — | EP | disclosed |
| US-20080027225-A1 | ISOTOPICALLY MARKED QUINOLINE DERIVATIVES AS ADENOSIN A3 RECEPTOR LIGANDS | SANOFI-AVENTIS (FR) | 2008-01-31 | — | — | US | disclosed |
| EP-1814857-A1 | ISOTOPICALLY MARKED QUINOLINE DERIVATIVES AS ADENOSIN A3 RECEPTOR LIGANDS | Sanofi-Aventis (FR) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006051341-A1 | ISOTOPICALLY MARKED QUINOLINE DERIVATIVES AS ADENOSIN A3 RECEPTOR LIGANDS | SANOFI-AVENTIS (FR) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027225-A1 | ISOTOPICALLY MARKED QUINOLINE DERIVATIVES AS ADENOSIN A3 RECEPTOR LIGANDS | ACKR3, ADORA3, CIAPIN1 | ADORA2A 8/4885ADORA1 28/4885LMNA 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.